Neuren Pharmaceuticals Limited (ASX:NEU) Insider Buys A$59,950.00 in Stock

Neuren Pharmaceuticals Limited (ASX:NEUGet Free Report) insider Joseph(Joe) Basile purchased 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The stock was acquired at an average price of A$11.99 ($7.74) per share, with a total value of A$59,950.00 ($38,677.42).

Neuren Pharmaceuticals Price Performance

Neuren Pharmaceuticals Company Profile

(Get Free Report)

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome.

See Also

Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with's FREE daily email newsletter.